Key clinical point: Both nivolumab and nivolumab plus ipilimumab were effective in patients with chemotherapy-refractory esophagogastric cancer.
Major finding: Treatment with nivolumab plus ipilimumab was associated with an objective response rate of 24%.
Study details: CheckMate-032 is an ongoing phase 1/2 trial involving 160 patients with metastatic or locally advanced chemotherapy-refractory esophageal, gastric, or gastroesophageal junction cancer from centers in Europe and the United States.
Disclosures: The study was supported by Bristol-Myers Squibb. The authors also reported funding from Merck, Incyte, Gilead Sciences, and others.
Janjigian YY et al. J Clin Oncol. 2018 Aug 15. doi: 10.1200/JCO.2017.76.6212.
This Week's Must Reads
Must Reads in Gastroenterology
ARAMIS: Darolutamide shines in nonmetastatic CRPC, Fizazi K et al. GUCS 2019, Abstract 140